Haemonetics Promotes Dr. Peter Tomasulo to Corporate Medical Director and Senior Vice President; New Red Cell Business Unit to Focus On Worldwide Opportunities.
BRAINTREE, Mass.--(BW HealthWire)--March 11, 1999--Haemonetics Corporation (NYSE NYSE
See: New York Stock Exchange :HAE) announced the promotion of Dr. Peter Tomasulo to Corporate Medical Director and Senior Vice President, Red Cell Business Unit. The Red Cell Business Unit is a new division created to provide dedicated focus on Haemonetics' opportunity to automate blood collection. The 40 million, manual blood donations “Give blood” redirects here. For other uses, see Give blood (disambiguation).
Blood donation is a process by which a blood donor voluntarily has blood drawn for storage in a blood bank, generally for subsequent use in a blood transfusion. made each year provide the target market for this Haemonetics' initiative.
Dr. Tomasulo joined Haemonetics in September, 1996. For the past year, he has led the successful effort to divest To deprive or take away.
Divest is usually used in reference to the relinquishment of authority, power, property, or title. If, for example, an individual is disinherited, he or she is divested of the right to inherit money. the Haemonetics' division which owned or operated US blood collection centers. Dr. Tomasulo is a graduate of the Johns Hopkins University School of Medicine The Johns Hopkins University School of Medicine, located in Baltimore, Maryland, USA, is a highly regarded medical school and biomedical research institute in the United States. and is certified in internal medicine, hematology, and blood banking. He spent 8 years in increasingly responsible management positions in the American Red Cross American Red Cross: see Red Cross. , ending his career as Chief Operating Officer Chief Operating Officer (COO)
The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of American Red Cross Blood Services which accepted 6 million blood donations per year under his responsibility. Dr. Tomasulo continued his career with the International Federation of Red Cross Societies in Geneva Geneva, canton and city, Switzerland
Geneva (jənē`və), Fr. Genève, canton (1990 pop. 373,019), 109 sq mi (282 sq km), SW Switzerland, surrounding the southwest tip of the Lake of Geneva. , Switzerland where he was Director of the Blood Department. In that capacity, he played a key role in the development of quality management systems in Red Cross blood programs throughout the world.
As Corporate Medical Director, Dr. Tomasulo will manage advanced development projects to insure that Haemonetics remains a forerunner in emerging technologies in the blood banking and autotransfusion industries. He will also seek long-term, strategic prospects for Haemonetics.
Red Blood Cell red blood cell: see blood. Market Opportunities
The Red Cell Business Unit is a new division. It will focus on bringing Haemonetics' automated blood collection technology to those blood centers and hospitals worldwide that continue to use "manual" blood collection techniques to collect blood from individuals. Haemonetics' technology automatically separates out a blood component (red cells, platelets, plasma) as the donation is progressing. Red cells are the blood component most in demand.
As Senior Vice President, Red Cell Business Unit, Dr. Tomasulo will have worldwide responsibility for the performance of the red cell business, including sales and profit contribution. He will manage a global, strategic plan to insure that progress is achieved in line with the Company's annual and long-term plans. He will specifically focus on next generation red cell products, and the Unit will provide the necessary regulatory and sales support to Haemonetics' worldwide sales organizations.
"The largest, near-term growth opportunity for Haemonetics is the successful implementation of our red cell programs. The establishment of the Red Cell Business Unit will ensure a dedicated and comprehensive focus during the next critical development phase of this new business," said Mr. James L. Peterson, Haemonetics' President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "We are the only company with the technology to collect two units of red blood cells Red blood cells
Cells that carry hemoglobin (the molecule that transports oxygen) and help remove wastes from tissues throughout the body.
Mentioned in: Bone Marrow Transplantation
red blood cells from a single donor. We are on the cusp of penetrating this market of 40 million procedures per year and converting these procedures to our proprietary, blood collection technology."
Haemonetics is a global company engaged in the design, manufacture, and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collections, and plasma collections. Over sixty percent of the Company's business is outside the US. To learn more about Haemonetics' products and markets, visit the Company's web site at http://www.haemonetics.com.